TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00006110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous infusion every 3 weeks for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous infusion every 3 weeks for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
Study: NCT00792116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum Chewing
Study: NCT01658397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Ten day fast
Study: NCT04219839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC + Educational Videos Designed Especially for post-transplant patients
Description: Patient focused videos (3-5 minutes each) with topics that will include: What to Expect After Transplant, What is the Kidney, Understanding your Labs, Transplant Medications, General Medical Care Post-Transplant, When to Call your Coordinator, and Self-Management/Sick Day protocols. Video curriculum will be offered in two ways. First, tablet computers with active links to each video will be available in kidney transplant clinic. At provider/coordinator discretion, study participants may also view videos while waiting for other appointments. In addition, for patients with smartphones who consent to this, a desktop link will be provided to the transplant video curriculum webpage (mobile friendly view).
Study: NCT00435188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component physical activity counseling program
Description: A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
Study: NCT02671214

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 100 g high fibre flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 2
Description: 98 g high fibre flour + 2 g guar gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 3
Description: 88 g high fibre flour + 2 g guar gum + 10 g legume flour
Study: NCT00960167

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT or IMRT
Description: All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT or IMRT
Description: All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT or IMRT
Description: All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3DCRT or IMRT
Description: All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)
Study: NCT03464474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital holographic microscopy
Description: Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
Study: NCT00509353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iobenguane I 131
Study: NCT03850405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark Chocolate
Description: 20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
Study: NCT03365453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frailty evaluation
Description: frailty and comorbidity scores
Study: NCT03722407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 5 mg tablets, 4 per dose
Study: NCT03337906

Intervention type: OTHER
Intervention: Observation
Study: NCT01476306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in this group will receive care as they usually do with the physician.
Study: NCT03951753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02623608

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reference breakfast
Description: A high fat, high calorie breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 1
Description: A high fat, high calorie breakfast including the Active Ingredient 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 2
Description: A high fat, high calorie breakfast including the Active Ingredient 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 3
Description: A high fat, high calorie breakfast including the Active Ingredient 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Ingredient 4
Description: A high fat, high calorie breakfast including the Active Ingredient 4
Study: NCT00098540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01990716

Intervention type: OTHER
Group type: OTHER
Intervention: Colonic Biopsy
Description: Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time.

Intervention type: OTHER
Group type: OTHER
Intervention: Colonic Biopsy
Description: Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time.
Study: NCT01587417

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 187004 CL
Description: 1 single dose per subject as oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004 CL
Description: 1 single dose per subject as oral solution
Study: NCT00989859

Intervention type: DEVICE
Intervention: Plethysmographic monitoring
Description: Plethysmographic monitoring
Study: NCT01790516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: daily radiation for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: daily radiation for 7 weeks
Study: NCT03001479

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid
Description: HMF with additional hydrolyzed protein
Study: NCT04106271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dyadic pain management program
Description: a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q \& A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
Study: NCT04929860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social marketing campaign
Description: social marketing campaign delivered over 4 weeks in 4 separate sessions
Study: NCT00135902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement
Description: Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 17 alpha-hydroxy progesterone caproate and Placebo supplement
Description: Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
Study: NCT02671214

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 4
Description: 83 g high fibre flour + 2 g guar gum + 15 g legume flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 5
Description: 96 g high fibre flour + 4 g guar gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 6
Description: 86 g high fibre flour + 4 g guar gum + 10 g legume flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 7
Description: 81 g high fibre flour + 4 g guar gum + 15 g legume flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 8
Description: 94 g high fibre flour + 6 g guar gum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 9
Description: 98 g high fibre flour + 2 g konjac mannan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 10
Description: 96 g high fibre flour + 4 g konjac mannan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 11
Description: 100 g low fibre flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active 1
Description: 85 g high fibre flour + 15 g legume flour
Study: NCT03712592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre and post running evaluations
Description: Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre and post running evaluations
Description: Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre and post running evaluations
Description: Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre and post running evaluations
Description: Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage.
Study: NCT03700372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOWA Approach Cardiac Ablation System
Description: Epicardial ablation using the IOWA Approach Cardiac Ablation System
Study: NCT03409731

Intervention type: DEVICE
Group type: OTHER
Intervention: ABSORB GT1 BVS
Description: Patients receiving Absorb GT1 BVS
Study: NCT02582385

Intervention type: OTHER
Intervention: in-situ cytokine expression

Intervention type: OTHER
Intervention: in-situ cytokine expression
Study: NCT01114672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50,000 Units Ergocalciferol
Description: 50,000 Units oral ergocalciferol to be given once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once weekly
Study: NCT02452099

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 5% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 7,5% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryopreservation of HSCs using 10% DMSO concentration
Description: Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
Study: NCT01537185

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 cohorts of normal saline injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 100 mcg
Description: 3 injections 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 600 mcg
Description: 3 injections 28 days apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPWCV+Alum 300 mcg
Description: 3 injections 28 days apart
Study: NCT00784745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2mg morning and night for 5 days.
Study: NCT04014790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGI-2001
Description: Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care prophylaxis regimen will be administered according to institutional guidelines
Study: NCT02460562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-PRG filler
Description: Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA resin
Description: Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA resin
Description: Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
Study: NCT03102866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic and strength training exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02323737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan and cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide and cisplatin
Study: NCT02620358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T Tube for 120 minuts
Description: Spontaneous Breathing Trial using T Tube for 120 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation of 8 cmH2O for 30 minutes
Description: Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
Study: NCT04103515

Intervention type: DEVICE
Intervention: Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
Description: Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty

Intervention type: DEVICE
Intervention: Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
Description: Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
Study: NCT00617513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 0.5 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study: NCT03818243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary (for reporting all impulse control disorders especially compulsive eating disorders)
Description: During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.